Maslinic acid inhibits proliferation of renal cell carcinoma cell lines and suppresses angiogenesis of endothelial cells

Parth Thakor, Wenzhe Song, Ramalingam B. Subramanian, Vasudev R. Thakkar, David A. Vesey, Glenda C Gobe

Abstract


Despite the introduction of many novel therapeutics in clinical practice, metastatic renal cell carcinoma (RCC) remains a treatment-re-sistant cancer. As red and processed meat are considered risk factors for RCC, and a vegetable-rich diet is thought to reduce this risk, research into plant-based therapeutics may provide valuable complementary or alternative therapeutics for the management of RCC. Herein, we present the antiproliferative and antiangiogenic effects of maslinic acid, which occurs naturally in edible plants, particularly in olive fruits, and also in a variety of medicinal plants. Human RCC cell lines (ACHN, Caki-1, and SN12K1), endothelial cells (human umbilical vein endothelial cell line [HUVEC]), and primary cultures of kidney proximal tubular epithelial cells (PTEC) were treated with maslinic acid. Maslinic acid was relatively less toxic to PTEC when compared with RCC under similar experimental conditions. In RCC cell lines, maslinic acid induced a significant reduction in proliferation, proliferating cell nuclear antigen, and colony formation. In HUVEC, maslinic acid induced a significant reduction in capillary tube formation in vitro and vascular endothelial growth factor. This study provides a rationale for incorporating a maslinic acid–rich diet either to reduce the risk of developing kidney cancer or as an adjunct to existing antiangiogenic therapy to improve efficacy.


Keywords


angiogenesis; maslinic acid; proliferating cell nuclear antigen; renal cell carcinoma; vascular endothelial growth factor

Full Text:

HTML PDF


DOI: http://dx.doi.org/10.15586/jkcvhl.2017.64

Article Metrics

Metrics Loading ...




Copyright (c) 2017 Parth Thakor, Glenda C Gobe

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.